Scoop: Novartis axes mid-stage depression trial of ketamine-like injection
09 Oct 2023
Phase 2AcquisitionClinical Trial Failure
Novartis has scrapped a Phase II clinical trial of an investigational treatment for major depressive disorder related to suicidal ideation, the Swiss Big Pharma confirmed to
Endpoints News
.
The decision was made “following a benefit risk assessment of available data,” a Novartis spokesperson said via email. The cull was disclosed in an Oct. 6
update
to the federal trials database.
Novartis was testing MIJ821, an IV injection, versus placebo to see if it was better at reducing depression symptoms. The nearly 200-patient trial began in July 2021 and wrapped up this July, per the
clinicaltrials.gov
entry. The company secured the asset through its $210 million upfront
buyout of Cadent Therapeutics
in 2020.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.